Display options
Cite
Mihályová J, Hradská K, Jelínek T, et al. Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders. Int J Mol Sci. 2021;22(21)doi: 10.3390/ijms222111470.
Mihályová, J., Hradská, K., Jelínek, T., Motais, B., Celichowski, P., & Hájek, R. (2021). Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders. International journal of molecular sciences, 22(21), . https://doi.org/10.3390/ijms222111470
Mihályová, Jana, et al. "Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders." International journal of molecular sciences vol. 22,21 (2021). doi: https://doi.org/10.3390/ijms222111470
Mihályová J, Hradská K, Jelínek T, Motais B, Celichowski P, Hájek R. Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders. Int J Mol Sci. 2021 Oct 25;22(21). doi: 10.3390/ijms222111470. PMID: 34768899; PMCID: PMC8584080.
Copy Download .nbib Format: NLM
Share it on

Int J Mol Sci. 2021 Oct 25;22(21). doi: 10.3390/ijms222111470.

Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders.

International journal of molecular sciences

Jana Mihályová, Katarína Hradská, Tomáš Jelínek, Benjamin Motais, Piotr Celichowski, Roman Hájek

Affiliations

  1. Department of Haematooncology, University Hospital Ostrava, 708 52 Ostrava, Czech Republic.
  2. Faculty of Medicine, University of Ostrava, 708 52 Ostrava, Czech Republic.

PMID: 34768899 PMCID: PMC8584080 DOI: 10.3390/ijms222111470

Abstract

Over the last few years, treatment principles have been changed towards more targeted therapy for many B-cell lymphoma subtypes and in chronic lymphocytic leukemia (CLL). Immunotherapeutic modalities, namely monoclonal antibodies (mAbs), bispecific antibodies (bsAbs), antibody-drug conjugates (ADCs), and chimeric antigen receptor T (CAR-T) cell therapy, commonly use B-cell-associated antigens (CD19, CD20, CD22, and CD79b) as one of their targets. T-cell engagers (TCEs), a subclass of bsAbs, work on a similar mechanism as CAR-T cell therapy without the need of previous T-cell manipulation. Currently, several anti-CD20xCD3 TCEs have demonstrated promising efficacy across different lymphoma subtypes with slightly better outcomes in the indolent subset. Anti-CD19xCD3 TCEs are being developed as well but only blinatumomab has been evaluated in clinical trials yet. The results are not so impressive as those with anti-CD19 CAR-T cell therapy. Antibody-drug conjugates targeting different B-cell antigens (CD30, CD79b, CD19) seem to be effective in combination with mAbs, standard chemoimmunotherapy, or immune checkpoint inhibitors. Further investigation will show whether immunotherapy alone or in combinatory regimens has potential to replace chemotherapeutic agents from the first line treatment.

Keywords: antibody-drug conjugates; bispecific antibodies; brentuximab vedotin; epcoritamab; glofitamab; immunotherapy; mosenutuzumab; polatuzumab vedotin

References

  1. Oncologist. 2019 May;24(5):e180-e187 - PubMed
  2. Blood. 2021 May 13;137(19):2634-2645 - PubMed
  3. Invest New Drugs. 2019 Apr;37(2):297-306 - PubMed
  4. J Clin Oncol. 2019 Nov 20;37(33):3081-3089 - PubMed
  5. Curr Oncol Rep. 2020 Jan 24;22(1):6 - PubMed
  6. Ann Oncol. 1999 Jun;10(6):655-61 - PubMed
  7. Front Oncol. 2020 Jan 22;9:1380 - PubMed
  8. Ther Adv Vaccines Immunother. 2018 Feb;6(1):3-17 - PubMed
  9. Cancer Discov. 2017 Dec;7(12):1404-1419 - PubMed
  10. Blood. 2012 Jun 28;119(26):6226-33 - PubMed
  11. Invest New Drugs. 2014 Dec;32(6):1246-57 - PubMed
  12. MAbs. 2021 Jan-Dec;13(1):1890411 - PubMed
  13. Blood. 2013 Feb 28;121(9):1612-21 - PubMed
  14. Acta Pharm Sin B. 2020 Sep;10(9):1589-1600 - PubMed
  15. Leuk Lymphoma. 2020 Dec;61(12):2905-2914 - PubMed
  16. Immunology. 2017 Nov;152(3):357-371 - PubMed
  17. Haematologica. 2018 Aug;103(8):1351-1358 - PubMed
  18. Int J Cancer. 2002 Aug 20;100(6):690-7 - PubMed
  19. Blood Adv. 2019 Aug 27;3(16):2491-2498 - PubMed
  20. Blood. 2016 Mar 17;127(11):1410-6 - PubMed
  21. Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):25-34 - PubMed
  22. Ther Adv Med Oncol. 2020 Oct 4;12:1758835920962997 - PubMed
  23. Invest New Drugs. 2018 Oct;36(5):869-876 - PubMed
  24. Br J Haematol. 2016 Jun;173(5):722-30 - PubMed
  25. Lancet. 2017 Aug 5;390(10094):555-566 - PubMed
  26. Br J Haematol. 2021 May;193(4):705-722 - PubMed
  27. Haematologica. 2021 Jun 01;106(6):1705-1713 - PubMed
  28. Drugs. 2021 Jul;81(10):1229-1233 - PubMed
  29. Cancer Immunol Immunother. 2006 Feb;55(2):210-20 - PubMed
  30. Int J Cancer. 2005 May 20;115(1):98-104 - PubMed
  31. Expert Rev Clin Pharmacol. 2020 Oct;13(10):1073-1083 - PubMed
  32. Blood. 2016 May 19;127(20):2375-90 - PubMed
  33. Molecules. 2021 Jan 25;26(3): - PubMed
  34. Lancet Oncol. 2015 Jan;16(1):57-66 - PubMed
  35. Blood. 2017 Apr 20;129(16):2328-2330 - PubMed
  36. Lancet. 2019 Jan 19;393(10168):229-240 - PubMed
  37. Haematologica. 2013 Dec;98(12):1930-8 - PubMed
  38. Mol Immunol. 2006 Feb;43(6):763-71 - PubMed
  39. Clin Lymphoma Myeloma Leuk. 2018 Jul;18(7):452-468.e4 - PubMed
  40. J Hematol Oncol. 2019 Sep 10;12(1):94 - PubMed
  41. Expert Opin Biol Ther. 2021 Jul;21(7):963-975 - PubMed
  42. Cancer Chemother Pharmacol. 2016 Jan;77(1):155-62 - PubMed
  43. Drug Discov Today. 2015 Jul;20(7):838-47 - PubMed
  44. J Clin Oncol. 2012 Jun 20;30(18):2183-9 - PubMed
  45. Lancet Oncol. 2019 Jul;20(7):998-1010 - PubMed
  46. MAbs. 2013 Nov-Dec;5(6):962-73 - PubMed
  47. J Clin Oncol. 2021 Jun 20;39(18):1959-1970 - PubMed
  48. Lancet Haematol. 2019 May;6(5):e254-e265 - PubMed
  49. Cytometry B Clin Cytom. 2019 Jan;96(1):20-29 - PubMed
  50. Drugs. 2019 Sep;79(13):1467-1475 - PubMed
  51. Leuk Lymphoma. 2020 Sep;61(9):2103-2112 - PubMed
  52. Haematologica. 2020 Jan 31;105(2):297-316 - PubMed
  53. Curr Hematol Malig Rep. 2020 Feb;15(1):9-19 - PubMed
  54. J Clin Oncol. 2020 Jan 10;38(2):155-165 - PubMed
  55. J Clin Invest. 2008 Jul;118(7):2427-37 - PubMed
  56. MAbs. 2015;7(3):584-604 - PubMed
  57. N Engl J Med. 2020 Apr 2;382(14):1331-1342 - PubMed
  58. Clin Chem Lab Med. 2006;44(7):775-96 - PubMed

Publication Types

Grant support